Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.4K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.

Journal of hematology & oncology·2021
Same author

Recent advances on blinatumomab for acute lymphoblastic leukemia.

Experimental hematology & oncology·2019
Same author

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.

Biomarker research·2019
Same author

Recent updates on CAR T clinical trials for multiple myeloma.

Molecular cancer·2019
Same author

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

Biomarker research·2019
Same author

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.

Journal of hematology & oncology·2019
Same journal

Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities.

Journal of hematology & oncology·2026
Same journal

Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting.

Journal of hematology & oncology·2026
Same journal

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment.

Journal of hematology & oncology·2026
Same journal

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.

Journal of hematology & oncology·2026
Same journal

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same journal

Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density.

Journal of hematology & oncology·2026
See all related articles

Related Experiment Video

Updated: Dec 8, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K

BCMA-targeted immunotherapy for multiple myeloma.

Bo Yu1, Tianbo Jiang2, Delong Liu3

  • 1Department of Medicine, Lincoln Medical Center, Bronx, NY, USA.

Journal of Hematology & Oncology
|September 18, 2020
PubMed
Summary
This summary is machine-generated.

B cell maturation antigen (BCMA) is a promising target for multiple myeloma (MM). BCMA-targeted therapies, including antibody-drug conjugates, show significant clinical responses in relapsed and refractory MM patients.

Keywords:
Antibody-drug conjugateB cell maturation antigenBCMABelantamab mafodotinBispecific T cell engagerCAR-T

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.5K

Related Experiment Videos

Last Updated: Dec 8, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.5K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • B cell maturation antigen (BCMA) is highly expressed on malignant plasma cells (PCs) in multiple myeloma (MM).
  • This selective expression makes BCMA an attractive therapeutic target for MM.
  • Relapsed and refractory MM patients have limited treatment options.

Purpose of the Study:

  • To review the molecular and physiological properties of BCMA.
  • To summarize BCMA-targeted immunotherapeutic agents in clinical development.
  • To discuss the therapeutic potential of BCMA-targeting drugs.

Main Methods:

  • Literature review of BCMA properties and targeted therapies.
  • Analysis of clinical trial data for BCMA-targeted agents.
  • Summary of approved and investigational BCMA therapeutics.

Main Results:

  • BCMA-targeted therapeutics, including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTEs), demonstrate significant clinical efficacy.
  • Belantamab mafodotin-blmf (a BCMA-targeted ADC) is approved for highly refractory MM.
  • Various BCMA-targeted agents are in different phases of clinical development.

Conclusions:

  • BCMA is a validated and effective target for multiple myeloma treatment.
  • BCMA-targeted immunotherapies offer new hope for patients with relapsed and refractory MM.
  • Continued research and development of BCMA-targeted agents are crucial for advancing MM therapy.